Abstract
The tyrosine kinase inhibitor STI571 exemplifies the successful development of a rationally designed, molecularly targeted therapy for the treatment of cancer. This review details the steps in the development of this agent and highlights why this drug has been so successful in the treatment of chronic myelogenous leukaemia. Future directions including the mechanisms and management of resistance and new therapeutic strategies are discussed. Finally, the literature supporting the use of STI571 in other malignancies, including solid tumors is briefly reviewed.
Keywords: Tyrosine Kinase Inhibitor, myelogenous leukaemia, Ph chromosome, allogeneic stem cell, optimal anti-leukemic effects, myelosuppression, CML blast crisis, Bcr-Abl associated leukemias, chronic myelomonocytic leukemic
Current Cancer Drug Targets
Title: The Role of the Tyrosine Kinase Inhibitor STI571 in the Treatment of Cancer
Volume: 1 Issue: 1
Author(s): Michael E. ODwyer and Brian J. Druker
Affiliation:
Keywords: Tyrosine Kinase Inhibitor, myelogenous leukaemia, Ph chromosome, allogeneic stem cell, optimal anti-leukemic effects, myelosuppression, CML blast crisis, Bcr-Abl associated leukemias, chronic myelomonocytic leukemic
Abstract: The tyrosine kinase inhibitor STI571 exemplifies the successful development of a rationally designed, molecularly targeted therapy for the treatment of cancer. This review details the steps in the development of this agent and highlights why this drug has been so successful in the treatment of chronic myelogenous leukaemia. Future directions including the mechanisms and management of resistance and new therapeutic strategies are discussed. Finally, the literature supporting the use of STI571 in other malignancies, including solid tumors is briefly reviewed.
Export Options
About this article
Cite this article as:
ODwyer E. Michael and Druker J. Brian, The Role of the Tyrosine Kinase Inhibitor STI571 in the Treatment of Cancer, Current Cancer Drug Targets 2001; 1 (1) . https://dx.doi.org/10.2174/1568009013334250
DOI https://dx.doi.org/10.2174/1568009013334250 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Liposomes: An Emerging Approach for the Treatment of Cancer
Current Pharmaceutical Design Exploring Proteomic Drug Targets, Therapeutic Strategies and Protein - Protein Interactions in Cancer: Mechanistic View
Current Cancer Drug Targets One Special Question to Start with: Can HIF/NFkB be a Target in Inflammation?
Endocrine, Metabolic & Immune Disorders - Drug Targets Towards Liver-Directed Gene Therapy for Crigler-Najjar Syndrome
Current Gene Therapy Personalized Medicine in a Consumer Age
Current Pharmacogenomics and Personalized Medicine Mechanisms Involved in Apoptosis Events Contributing to Sepsis-Induced Myocardial Dysfunction
Current Drug Therapy Bruton Kinase Inhibitors in Chronic Lymphocytic Leukemia
Anti-Cancer Agents in Medicinal Chemistry Application of Artificial Neural Networks for the Prediction of Antitumor Activity of a Series of Acridinone Derivatives
Medicinal Chemistry Design, Synthesis and Biochemical Evaluation of Estrogen Receptor Ligand Conjugates as Tumour Targeting Agents
Letters in Drug Design & Discovery Summary of Information on the Effects of Ionizing and Non-ionizing Radiation on Cytochrome P450 and Other Drug Metabolizing Enzymes and Transporters
Current Drug Metabolism Cytotoxic, Apoptotic and DNA Synthesis Inhibitory Effects of Some Thiazole Derivatives
Letters in Drug Design & Discovery Microwave-assisted Cycloaddition Reactions in Carbo- and Heterocyclic Chemistry
Current Organic Chemistry Anticancer Drugs in Liposomal Nanodevices: A Target Delivery for a Targeted Therapy
Current Topics in Medicinal Chemistry Genomics and Proteomics of Nucleoside Transporters
Current Pharmacogenomics Transposons for Gene Therapy!
Current Gene Therapy An Update on Natural Occurrence and Biological Activity of Chromones
Current Medicinal Chemistry Doxycycline as Potential Anti-cancer Agent
Anti-Cancer Agents in Medicinal Chemistry Trends in the Exploration of Anticancer Targets and Strategies in Enhancing the Efficacy of Drug Targeting
Current Molecular Pharmacology Clinical Applications of the Urokinase Receptor (uPAR) for Cancer Patients
Current Pharmaceutical Design Yeast as a Powerful Model System for the Study of Apoptosis Regulation by Protein Kinase C Isoforms
Current Pharmaceutical Design